ES2115055T3 - 1-fenil-2-(2-piridinil)etilamina enantiomera para el tratamiento de trastornos neurodegenerativos. - Google Patents

1-fenil-2-(2-piridinil)etilamina enantiomera para el tratamiento de trastornos neurodegenerativos.

Info

Publication number
ES2115055T3
ES2115055T3 ES93907975T ES93907975T ES2115055T3 ES 2115055 T3 ES2115055 T3 ES 2115055T3 ES 93907975 T ES93907975 T ES 93907975T ES 93907975 T ES93907975 T ES 93907975T ES 2115055 T3 ES2115055 T3 ES 2115055T3
Authority
ES
Spain
Prior art keywords
phenyl
treatment
neurodegenerative disorders
enantiomera
piridinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93907975T
Other languages
English (en)
Inventor
Ronald Conrad Griffith
Robert John Murray
Michael Balestra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Astra AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929207339A external-priority patent/GB9207339D0/en
Priority claimed from GB929208290A external-priority patent/GB9208290D0/en
Application filed by Astra AB filed Critical Astra AB
Application granted granted Critical
Publication of ES2115055T3 publication Critical patent/ES2115055T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

EL (S)COLOGICAMENTE ACEPTABLES, SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES NEURODEGENERATIVAS, Y EXHIBEN FARMACOCINETICOS LINEALES.
ES93907975T 1992-04-03 1993-04-01 1-fenil-2-(2-piridinil)etilamina enantiomera para el tratamiento de trastornos neurodegenerativos. Expired - Lifetime ES2115055T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929207339A GB9207339D0 (en) 1992-04-03 1992-04-03 Pharmaceutical compound
GB929208290A GB9208290D0 (en) 1992-04-15 1992-04-15 Pharmaceutical compound having neuroprotective properties

Publications (1)

Publication Number Publication Date
ES2115055T3 true ES2115055T3 (es) 1998-06-16

Family

ID=26300643

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93907975T Expired - Lifetime ES2115055T3 (es) 1992-04-03 1993-04-01 1-fenil-2-(2-piridinil)etilamina enantiomera para el tratamiento de trastornos neurodegenerativos.

Country Status (29)

Country Link
EP (1) EP0633879B1 (es)
JP (2) JP3120810B2 (es)
KR (1) KR100259567B1 (es)
CN (1) CN1044367C (es)
AT (1) ATE163925T1 (es)
AU (2) AU3897693A (es)
CA (1) CA2133427C (es)
CZ (1) CZ288519B6 (es)
DE (1) DE69317411T2 (es)
DK (1) DK0633879T3 (es)
DZ (1) DZ1677A1 (es)
ES (1) ES2115055T3 (es)
FI (1) FI105025B (es)
HK (1) HK1009331A1 (es)
HU (1) HU211529A9 (es)
IL (1) IL105276A (es)
MA (1) MA22866A1 (es)
MX (1) MX9301935A (es)
MY (1) MY110149A (es)
NO (1) NO302170B1 (es)
NZ (1) NZ251384A (es)
PL (1) PL180014B1 (es)
RU (1) RU2128650C1 (es)
SG (1) SG47948A1 (es)
SK (1) SK281258B6 (es)
TW (1) TW282455B (es)
UA (1) UA29437C2 (es)
WO (1) WO1993020052A1 (es)
ZA (1) ZA932415B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9320273D0 (en) * 1993-04-01 1993-11-17 Fisons Corp Compound useful in therapy
ATE135206T1 (de) * 1988-08-12 1996-03-15 Astra Ab Arylalkylamine und -amide mit krampflösender und nervenschützender wirkung
ZA942140B (en) * 1993-04-01 1994-10-03 Fisons Corp Salt of (S)-alpha-phenyl-2-pyridineethanamine useful in therapy
SE9901077D0 (sv) * 1999-03-23 1999-03-23 Astra Ab Novel use
SE9901237D0 (sv) * 1999-04-06 1999-04-06 Astra Ab Novel use
SE9901340D0 (sv) 1999-04-15 1999-04-15 Astra Pharma Prod Novel process
WO2007017652A2 (en) * 2005-08-10 2007-02-15 Astrazeneca Ab Arylakylamines for the treatment of cancer
EA201190064A1 (ru) * 2008-12-24 2012-02-28 Астразенека Аб Соединения этанамина и их применение для лечения депрессии
CN104114714A (zh) * 2011-12-14 2014-10-22 阿斯利康(瑞典)有限公司 Gabr-a2诊断
WO2015067923A1 (en) * 2013-11-05 2015-05-14 Astrazeneca Ab Nmda antagonist prodrugs
CA3187140A1 (en) * 2020-06-23 2021-12-30 Biohaven Therapeutics Ltd. Topical formulations of (1s)-1-phenyl-2-pyridin-2-ylethanamine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE135206T1 (de) * 1988-08-12 1996-03-15 Astra Ab Arylalkylamine und -amide mit krampflösender und nervenschützender wirkung

Also Published As

Publication number Publication date
SK281258B6 (sk) 2001-01-18
EP0633879B1 (en) 1998-03-11
KR100259567B1 (ko) 2000-07-01
PL180014B1 (pl) 2000-11-30
TW282455B (es) 1996-08-01
EP0633879A1 (en) 1995-01-18
AU7545696A (en) 1997-02-13
ATE163925T1 (de) 1998-03-15
JP2000319259A (ja) 2000-11-21
MY110149A (en) 1998-02-28
NO943645D0 (no) 1994-09-30
CA2133427C (en) 2003-06-10
RU94042465A (ru) 1996-07-20
NO943645L (no) 1994-11-16
HK1009331A1 (en) 1999-05-28
CN1044367C (zh) 1999-07-28
AU705419B2 (en) 1999-05-20
JPH07505385A (ja) 1995-06-15
SG47948A1 (en) 1998-04-17
SK117794A3 (en) 1995-05-10
DK0633879T3 (da) 1998-09-28
IL105276A (en) 1997-06-10
RU2128650C1 (ru) 1999-04-10
MX9301935A (es) 1994-08-31
FI105025B (fi) 2000-05-31
AU3897693A (en) 1993-11-08
IL105276A0 (en) 1993-08-18
NO302170B1 (no) 1998-02-02
NZ251384A (en) 1996-10-28
CN1081669A (zh) 1994-02-09
CA2133427A1 (en) 1993-10-14
ZA932415B (en) 1993-10-22
JP3120810B2 (ja) 2000-12-25
WO1993020052A1 (en) 1993-10-14
MA22866A1 (fr) 1993-12-31
FI944546A (fi) 1994-09-30
UA29437C2 (uk) 2000-11-15
CZ288519B6 (cs) 2001-07-11
DE69317411T2 (de) 1998-07-30
CZ240994A3 (en) 1995-12-13
DE69317411D1 (de) 1998-04-16
DZ1677A1 (fr) 2002-02-17
FI944546A0 (fi) 1994-09-30
HU211529A9 (en) 1995-11-28

Similar Documents

Publication Publication Date Title
DK0386997T3 (da) Anvendelse af 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamin-derivater i behandlingen af psykose, inflammation og som immunosuppressive midler
ES2186667T3 (es) Analogos de nucleosidos de 1,3-oxatiolano.
ITRM920412A1 (it) Eteroprostanoidi, procedimento per la loro preparazione e loro impiego terapeutico.
DE498268T1 (de) 5-oxo-l-prolinderivate und deren pharmazeutischen herstellungen.
ES2115055T3 (es) 1-fenil-2-(2-piridinil)etilamina enantiomera para el tratamiento de trastornos neurodegenerativos.
ITMI911470A0 (it) N-(5-tioxo-l-prolil)-l-cisteina e suoi derivati, loro preparazione ed impiego terapeutico
PT656209E (pt) Derivados de melatonina para uso no tratamento de perturbacoes de dessincronizacao
EP0342427A3 (de) Strobilurinderivate, ihre Herstellung und Verwendung
MX9201610A (es) Proceso para el tratamiento de una aleacion argentifera.
ES1030600Y (es) Mesa perfeccionada para el soporte y utilizacion de instrumentos oftalmologicos y optpmetricos.
ES1023616Y (es) Estructura plegable perfeccionada, para sillas de minusvalidos y similares.
ITMI931684A0 (it) Procedimento per la preparazione di derivati del 5,4- diidrocarbostirile
ES1016656Y (es) Punta activa para piezas de tornilleria.
ITRM930654A0 (it) Derivati guanidinici ad uso terapeutico.
ES1026655Y (es) Dispositivo perfeccionado para el accionamiento de pantografos.
ES1016910Y (es) Maquina perfeccionada para el tratamiento de material laminar.
BR9202705A (pt) Cadeira de rodas para banho e necessidades disiologicas,dobravel e parcialmente desmontavel
IT1263076B (it) Uso orale e topico della n-acetil-5-metossitriptamina (melatonina) nella terapia della psoriasi volgare.
ES1023093Y (es) "asiento perfeccionado, para muebles"
YU104192A (sh) 2-(4-hidroksipiperiodino)-1-alkanol derivati
ES1020321Y (es) Dispositivo perfeccionado para aleros deslizables para mesas.
ES1025571Y (es) Estructura perfeccionada para mesas de oficina y similares
MX9100453A (es) Derivados azaciclicos y proceso para su preparacion.
ES1024962Y (es) Marco perfeccionado para cuadros y similares.
ES1025329Y (es) Marco perfeccionado para cuadros y similares.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 633879

Country of ref document: ES